Overview
Drug-induced neutropenia is a hematological adverse reaction characterized by a significant decrease in neutrophil count due to medication use, often complicating inpatient care and affecting various patient populations 1.Diagnosis
Clinical Presentation: Neutrophil count below the lower threshold of normal, typically <1.5 × 10^9/L 1.
Evaluation: Comprehensive review of medication history, including recent drug exposures and dosages 1.
Laboratory Tests: Regular complete blood count (CBC) monitoring to detect neutropenia 1.
Causality Assessment: Use of standardized tools like Naranjo or WHO-UMC criteria to assess drug causality 1.Management
Withdrawal of Suspected Drug: Immediate discontinuation of the implicated medication 1.
Supportive Care: Administration of granulocyte colony-stimulating factor (G-CSF) for severe cases to accelerate neutrophil recovery 1.
Infection Prophylaxis: Vigilant monitoring for and prompt treatment of infections due to neutropenia 1.
Adjunctive Treatments: Consideration of broad-spectrum antibiotics if fever or signs of infection are present 1.Special Populations
Pediatrics: Higher incidence of adverse drug reactions, particularly with drugs like asparaginase, methotrexate, and phenytoin; careful monitoring essential 2.
Elderly: Increased risk associated with multiple comorbidities and polypharmacy; longer hospital stays correlate with higher ADR frequency 1.
Comorbidities: Chronic renal failure noted as a risk factor for increased adverse drug reactions 1.Key Recommendations
Conduct regular CBC monitoring in hospitalized patients, especially those on multiple medications, to early detect drug-induced neutropenia (Evidence: Moderate 1).
Promptly discontinue suspected drugs upon identifying a causal link to neutropenia (Evidence: Moderate 1).
Initiate G-CSF therapy for severe neutropenia to support neutrophil recovery (Evidence: Moderate 1).
Enhance surveillance and infection prophylaxis in pediatric patients due to higher ADR susceptibility (Evidence: Moderate 2).
Tailor medication management in elderly patients considering their increased risk from comorbidities and polypharmacy (Evidence: Moderate 1).References
1 Ribeiro MR, Motta AA, Marcondes-Fonseca LA, Kalil-Filho J, Giavina-Bianchi P. Increase of 10% in the Rate of Adverse Drug Reactions for Each Drug Administered in Hospitalized Patients. Clinics (Sao Paulo, Brazil) 2018. link
2 González-Martin G, Caroca CM, Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study. International journal of clinical pharmacology and therapeutics 1998. link